相似文献
1
Targeting of multidrug-resistant human ovarian carcinoma cells with anti-P-glycoprotein antibody conjugates.
Macromol Biosci. 2012 Apr;12(4):502-14. doi: 10.1002/mabi.201100350. Epub 2012 Jan 25.
2
HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line.
J Control Release. 1998 Jul 31;54(2):223-33. doi: 10.1016/s0168-3659(98)00009-1.
3
Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate.
J Control Release. 1998 Apr 30;53(1-3):25-37. doi: 10.1016/s0168-3659(97)00235-6.
4
Chronic exposure of human ovarian carcinoma cells to free or HPMA copolymer-bound mesochlorin e6 does not induce P-glycoprotein-mediated multidrug resistance.
Biomaterials. 2000 Nov;21(21):2203-10. doi: 10.1016/s0142-9612(00)00161-7.
5
HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. II. Processing in epithelial ovarian carcinoma cells in vitro.
Int J Cancer. 1998 Feb 9;75(4):600-8. doi: 10.1002/(sici)1097-0215(19980209)75:4<600::aid-ijc18>3.0.co;2-c.
6
HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. 3. The effect of free and polymer-bound adriamycin on the expression of some genes in the OVCAR-3 human ovarian carcinoma cell line.
Eur J Pharm Biopharm. 2000 Jan;49(1):11-5. doi: 10.1016/s0939-6411(99)00033-8.
7
Cooperativity between free and N-(2-hydroxypropyl) methacrylamide copolymer bound adriamycin and meso-chlorin e6 monoethylene diamine induced photodynamic therapy in human epithelial ovarian carcinoma in vitro.
Int J Oncol. 1999 Jul;15(1):5-16. doi: 10.3892/ijo.15.1.5.
8
The strong in vivo anti-tumor effect of the UIC2 monoclonal antibody is the combined result of Pgp inhibition and antibody dependent cell-mediated cytotoxicity.
PLoS One. 2014 Sep 19;9(9):e107875. doi: 10.1371/journal.pone.0107875. eCollection 2014.
9
A possibility to overcome P-glycoprotein (PGP)-mediated multidrug resistance by antibody-targeted drugs conjugated to N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer carrier.
Eur J Cancer. 1999 Mar;35(3):459-66. doi: 10.1016/s0959-8049(98)00373-6.
10
Star structure of antibody-targeted HPMA copolymer-bound doxorubicin: a novel type of polymeric conjugate for targeted drug delivery with potent antitumor effect.
Bioconjug Chem. 2002 Mar-Apr;13(2):206-15. doi: 10.1021/bc010063m.
引用本文的文献
1
ML210 Antagonizes ABCB1- Not ABCG2-Mediated Multidrug Resistance in Colorectal Cancer.
Biomedicines. 2025 May 20;13(5):1245. doi: 10.3390/biomedicines13051245.
2
Polymer Conjugate as the New Promising Drug Delivery System for Combination Therapy against Cancer.
Curr Top Med Chem. 2024;24(13):1101-1119. doi: 10.2174/0115680266280603240321064308.
3
Photodynamic priming modulates cellular ATP levels to overcome P-glycoprotein-mediated drug efflux in chemoresistant triple-negative breast cancer.
Photochem Photobiol. 2025 Jan-Feb;101(1):188-205. doi: 10.1111/php.13970. Epub 2024 Jun 2.
4
Polymer nanomedicines.
Adv Drug Deliv Rev. 2020;156:40-64. doi: 10.1016/j.addr.2020.07.020. Epub 2020 Jul 28.
5
Photoimmunotherapy of Ovarian Cancer: A Unique Niche in the Management of Advanced Disease.
Cancers (Basel). 2019 Nov 27;11(12):1887. doi: 10.3390/cancers11121887.
6
Backbone Degradable N-(2-Hydroxypropyl)methacrylamide Copolymer Conjugates with Gemcitabine and Paclitaxel: Impact of Molecular Weight on Activity toward Human Ovarian Carcinoma Xenografts.
Mol Pharm. 2017 May 1;14(5):1384-1394. doi: 10.1021/acs.molpharmaceut.6b01005. Epub 2017 Feb 3.
7
Targeting ABCB1-mediated tumor multidrug resistance by CRISPR/Cas9-based genome editing.
Am J Transl Res. 2016 Sep 15;8(9):3986-3994. eCollection 2016.
8
Design of smart HPMA copolymer-based nanomedicines.
J Control Release. 2016 Oct 28;240:9-23. doi: 10.1016/j.jconrel.2015.10.003. Epub 2015 Oct 3.
9
Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance.
Nano Today. 2012 Aug 1;7(4):367-379. doi: 10.1016/j.nantod.2012.06.013.
10
Polymer-drug conjugates: origins, progress to date and future directions.
Adv Drug Deliv Rev. 2013 Jan;65(1):49-59. doi: 10.1016/j.addr.2012.10.014. Epub 2012 Nov 2.
本文引用的文献
1
Pgp inhibition by UIC2 antibody can be followed in vitro by using tumor-diagnostic radiotracers, 99mTc-MIBI and 18FDG.
Eur J Pharm Sci. 2010 Dec 23;41(5):665-9. doi: 10.1016/j.ejps.2010.09.009. Epub 2010 Oct 1.
2
Spectral analysis of doxorubicin accumulation and the indirect quantification of its DNA intercalation.
Eur J Pharm Biopharm. 2010 Nov;76(3):514-24. doi: 10.1016/j.ejpb.2010.07.008. Epub 2010 Jul 16.
3
Rab4 interacts with the human P-glycoprotein and modulates its surface expression in multidrug resistant K562 cells.
Int J Cancer. 2011 Jan 1;128(1):192-205. doi: 10.1002/ijc.25310.
4
Rapid, reversible modulation of blood-brain barrier P-glycoprotein transport activity by vascular endothelial growth factor.
J Neurosci. 2010 Jan 27;30(4):1417-25. doi: 10.1523/JNEUROSCI.5103-09.2010.
5
Anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia.
MAbs. 2009 Sep-Oct;1(5):481-90. doi: 10.4161/mabs.1.5.9288. Epub 2009 Sep 15.
6
Do HPMA copolymer conjugates have a future as clinically useful nanomedicines? A critical overview of current status and future opportunities.
Adv Drug Deliv Rev. 2010 Feb 17;62(2):272-82. doi: 10.1016/j.addr.2009.12.005. Epub 2009 Dec 11.
7
HPMA copolymers: origins, early developments, present, and future.
Adv Drug Deliv Rev. 2010 Feb 17;62(2):122-49. doi: 10.1016/j.addr.2009.10.004. Epub 2009 Nov 14.
8
Abrogating drug resistance in malignant peripheral nerve sheath tumors by disrupting hyaluronan-CD44 interactions with small hyaluronan oligosaccharides.
Cancer Res. 2009 Jun 15;69(12):4992-8. doi: 10.1158/0008-5472.CAN-09-0143. Epub 2009 May 26.
9
Multidrug resistance through the spectacle of P-glycoprotein.
Curr Cancer Drug Targets. 2009 May;9(3):281-97. doi: 10.2174/156800909788166493.
10
Biorecognition and subcellular trafficking of HPMA copolymer-anti-PSMA antibody conjugates by prostate cancer cells.
Mol Pharm. 2009 May-Jun;6(3):959-70. doi: 10.1021/mp8002682.
Zotero 插件